Chairman of the Egyptian Drug Authority, Ali el-Ghamrawy, received on Wednesday a high-level delegation from the Republic of Eritrea to discuss avenues for strengthening co-operation in the pharmaceutical sector.
The delegation was headed by Advisor to the Eritrean President for Economic Affairs Hagos Gebrehiwet, and included Minister of Trade and Industry Naseer el-Din Mohamed Saleh, in the presence of Deputy Assistant Minister of Foreign Affairs Ambassador Mohamed Safwat.
The visit reflects the depth of bilateral relations and the mutual commitment to expanding co-operation in this vital field.
At the outset of the meeting, Chairman el-Ghamrawy welcomed the delegation, expressing the authority’s pride in the strong ties between Egypt and Eritrea and its readiness to enhance collaboration and exchange expertise in pharmaceutical regulation and control.
He noted that such co-operation supports the development and efficiency of health systems at both regional and international levels.
During the discussions, the chairman underscored the authority’s priority to strengthen regional and international partnerships in drug regulation.
He highlighted that the progress achieved within Egypt’s pharmaceutical sector is the result of a clear strategic vision and integrated institutional efforts aimed at ensuring the availability of safe and effective medicines in line with the latest international standards.
For their part, members of the Eritrean delegation commended the advanced regulatory framework of EDA, particularly Egypt’s attainment of Maturity Level 3 under the World Health Organisation’s evaluation system, reflecting strong institutional performance and international confidence in the national pharmaceutical system.
The meeting also explored mechanisms for enhancing co-operation between authority and Eritrea’s National Medicines and Food Administration, particularly in pharmaceutical registration, quality control, and regulatory capacity-building.
The authority affirmed that this visit underscores its leading role as a regional model in Africa and its continued efforts to support the development of pharmaceutical systems and improve access to safe and effective medical products.
